Expertise in
68
conditions

Dr. Rachit A. Kumar

Hematology Oncology | Hematology | Oncology
Virginia Cancer Institute Incorporated
8007 Discovery Dr, Suite A, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
16 Years of Experience
Expertise in
68
conditions
Virginia Cancer Institute Incorporated
8007 Discovery Dr, Suite A, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rachit Kumar is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Kumar has been practicing medicine for over 16 years is highly rated in 68 conditions, according to our data. His top areas of expertise are Lung Cancer, Pancreatic Cancer, Pleuropulmonary Blastoma, Pancreaticoduodenectomy, and Liver Embolization. Dr. Kumar is currently accepting new patients.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in ME
Hospital Affiliations
Henrico Doctors' Hospital
Cjw Medical Center
Bon Secours St Marys Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

VIRGINIA CANCER INSTITUTE INCORPORATED
8007 Discovery Dr, Suite A, Richmond, VA 23229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Other, Drug
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: September 23, 2024
Intervention Type: Drug
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

81 Total Publications

Integrative multi-omics approaches identify molecular pathways and improve Alzheimer's Disease risk prediction.
Integrative multi-omics approaches identify molecular pathways and improve Alzheimer's Disease risk prediction.
Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Craig A. Portell
Hematology Oncology | Hematology | Oncology
Expertise in
29
conditions
Dr. Craig A. Portell
Hematology Oncology | Hematology | Oncology

University Of Virginia Physicians Group

1240 Lee St, 
Charlottesville, VA 
 (59.1 miles away)
434-243-0321
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Portell is a Hematologist Oncology specialist and a Hematologist in Charlottesville, Virginia. Dr. Portell is highly rated in 29 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Portell is currently accepting new patients.

Expertise in
15
conditions
Dr. William J. Irvin
Hematology Oncology | Hematology | Oncology
Expertise in
15
conditions
Dr. William J. Irvin
Hematology Oncology | Hematology | Oncology

Bon Secours-Richmond Community Hospital LLC

5875 Bremo Rd, Suite 209, 
Richmond, VA 
 (3.3 miles away)
804-287-7804
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Irvin is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Irvin is highly rated in 15 conditions, according to our data. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Irvin is currently accepting new patients.

Expertise in
32
conditions
Dr. Victor Y. Yazbeck
Hematology Oncology | Hematology | Oncology
Expertise in
32
conditions
Dr. Victor Y. Yazbeck
Hematology Oncology | Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (6.6 miles away)
804-828-7929
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Victor Yazbeck is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Yazbeck is highly rated in 32 conditions, according to our data. His top areas of expertise are Prolymphocytic Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy. Dr. Yazbeck is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
    View All 66 Advanced Conditions
    View All 171 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile